Oncimmune losses deepen on higher R&D and administrative spending

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 08:26

Immunodiagnostics system supplier Oncimmune Holdings said its annual losses deepened as it increased R&D spending.

Pre-tax losses for the year through November amounted to £3.9m, compared to losses of £2.8m on-year.

R&D spending rose to £0.7m, from £0.5m, while administrative expenses also rose.

Revenue nudged up to £121k, from £77k).

'Aligned with the forward strategy, and with the support of Oncimmune's new Scientific Board, our R&D programme has been focused on exploring the potential of tumour-related antibodies as combined and complementary diagnostic tests,' chief executive Adam Hill said.

'Our commercial effort has concentrated on developing propositions for the diagnostic and pharmaceutical industry to maximise the latent potential of Oncimmune's immunogenic protein platform.'

At 8:26am: (LON:ONC) Oncimmune Holdings Plc share price was -8p at 88.5p


Related content

Oncimmune inks distribution agreement in Portugal and Spain with Sabartech

Cancer diagnostics group Oncimmune Holdings said it had signed an exclusive agreement for the distribution of its lung cancer test kit in Portugal with Sabartech,...

Fri, 05/04/2019 - 07:13


Oncimmune partner in Colombia receives regulatory nod for diagnostics product

Oncimmune Holdings said its distributor in Columbia, Valentech International, had obtained regulatory approval for the sale of its lung cancer diagnostics product.

Oncimmune had an...

Mon, 01/04/2019 - 07:56


Oncimmune inks new supply agreement in Spain with Quironsalud

Immunodiagnostics group Oncimmune Holdings said its Spanish distributor, Sabartech, hade signed a new supply agreement with Quironsalud.

The agreement would involve Oncimmune's EarlyCDT-Lung technology being...

Mon, 25/03/2019 - 09:58


Oncimmune acquires Protagen Diagnostics for up to £4.1m

Cancer diagnostics group Oncimmune Holdings said it had acquired Protagen Diagnostics for up to £4.1m.

The deal would be funded by the allotment of up...

Tue, 19/03/2019 - 08:20


Oncimmune losses deepen, warns on revenue after partner talks collapse

Immunodiagnostics group Oncimmune Holdings posted a deeper annual loss and cut its revenue expectations for the current year due to the collapse of talks with...

Wed, 31/10/2018 - 08:41